Table 1.
Summary of antitumor activity and safety profile of evofosfamide monotherapy, everolimus or temsirolimus monotherapy, and evofosfamide in combination with mTOR inhibitors in the 786-O and Caki-1 RCC xenograft models
| 786-O (mTORi: Eve) | 786-O (mTORi: Tem) | Caki-1 (mTORi: Eve) | Caki-1 mTORi: Tem) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||
| TGI % | MBL % | TGI % | MBL % | TGI % | TGD1000 | MBL % | TGI % | TGD1000 | MBL % | |
| mTORi | 48* | 0 | 113* | 3 | 52* | 10 | 1 | 74* | 17 | 4 |
| Evofosfamide CS | 15 | 0 | 0 | 7 | 57* | 10 | 0 | 75* | 19 | 2 |
| mTORi + Evo CS | 84*,a,b | 0 | 136*,a,b | 9 | 87*,a,b | 24 | 4 | 96*,a,b | 24 | 9 |
| Evofosfamide DS | 25 | 0 | 14 | 0 | 81* | 19 | 0 | |||
| mTORi + Evo DS | 83*,a,b | 0 | 142*,a,b | 8 | 94*,a,b | 32 | 7 | |||
TGI, Tumor Growth Inhibition; TGD1000, Tumor Growth Delay to Vehicle reaching the size of 1000 mm3; MBL, maximal body weight loss due to drug treatment as compared with the first day of treatment; Evo, evofosfamide; mTORi, mTOR inhibitor; Eve, everolimus; Tem, temsirolimus; CS, concurrent schedule in which evofosfamide was given from Day 1 for 3 weeks; DS, delayed schedule in which evofosfamide was given from Day 8 for 2 weeks;
P<0.05 compared with Vehicle.
P < 0.05 as compared to mTOR inhibitor monotherapy.
P < 0.05 as compared to evofosfamide monotherapy.